| COMPANY COUNTRY | USA |
| COOPERATION | UK's firm (see alliance & Literature Ref) has developed a commercial asymmetric hydrogenation for said intermediate (see Synthesis) |
| CLASSIFICATION | Licens. Market |
| INDICATION'S |
Atrial Natriuretic Factor Potentiator Congestive Heart Failure Treat Hypertension Treat |
| MARKETER'S COUNTRY | USA |
| PRODUCER'S COUNTRY | USA |
| SYNTHESIS |
The process uses (R,R)-Me-DuPHOS, which is a chiral bis (tetramethylphospholidine) ligand that UK's firm licensed from USA firm (See licensor) |
| UPDATE | 10.99 |
| ALLIANCE | This data is not available for free |
| AUTHOR | This data is not available for free |
| LICENSEE | This data is not available for free |
| LICENSOR | This data is not available for free |
| LITERATURE REF. | This data is not available for free |
| MARKETING BY | This data is not available for free |
| PRODUCTION BY | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |